Nanotechnology has ushered in a new era of medical innovation, offering unique solutions to longstanding healthcare challenges. Among nanomaterials, copper and copper oxide nanoparticles stand out as promising candidates for a multitude of medical applications. This article aims to provide contemporary insights into the perspectives and challenges regarding the use of copper and copper oxide nanoparticles in medicine. It summarises the biomedical potential of copper-based nanoformulations, including the progress of early-stage research, to evaluate and mitigate the potential toxicity of copper nanomaterials. The discussion covers the challenges and prospects of copper-based nanomaterials in the context of their successful clinical translation. The article also addresses safety concerns, emphasizing the need for toxicity assessments of nanomedicines. However, attention is needed to solve the current challenges such as biocompatibility and controlled release. Ongoing research and collaborative efforts to overcome these obstacles are discussed. This analysis aims to provide guidance for the safe and effective integration of copper nanoparticles into clinical practice, thereby advancing their medical applications. This analysis of recent literature has highlighted the multifaceted challenges and prospects associated with copper-based nanomaterials in the context of their translation from the laboratory to the clinic. In particular, biocompatibility remains a formidable hurdle, requiring innovative solutions to ensure the seamless integration into the human body. Additionally, achieving the controlled release of therapeutic agents from copper nanoparticles poses a complex challenge that requires meticulous engineering and precise design.

Many bacteria become progressively more resistant to antibiotics and it remains a challenging task to control their overall levels. Polymers combined with active biomolecules come to the forefront for the design of antibacterial materials that can address this encounter. In this work, we investigated the photo-crosslinking approach of UV-sensitive benzophenone molecule (BP) with polyvinylpyrrolidone (PVP) polymer within electrospun fibres. The BP and PVP solutions allowed fabricating polymer mats that were subsequently functionalised with antibacterial lysozyme. The physical properties of the crosslinked electrospun fibres were investigated by scanning electron microscopy and atomic force microscopy. The average diameter of the obtained fibres decreased from 290 ± 50 nm to 270 ± 70 nm upon the addition of the crosslinking molecules and then to 240 ± 80 nm and 180 ± 90 nm after subsequent crosslinking reaction at an increasing time: 3 and 5 h, respectively. The peak force quantitative nanomechanical mapping (PF-QNM) indicated the increase of DMT modulus of obtained cross-linked fibres from 4.1 ± 0.8 GPa to 7.2 ± 0.5 GPa. Furthermore, the successful crosslinking reaction of PVP and BP solution into hydrogels was investigated in terms of examining photo-crosslinking mechanism and was confirmed by rheology, Raman, Fourier transform infrared and nuclear magnetic resonance. Finally, lysozyme was successfully encapsulated within cross-linked PVP-BP hydrogels and these were successfully electrospun into mats which were found to be as effective antibacterial agents as pure lysozyme molecules. The dissolution rate of photo cross-linked PVP mats was observed to increase in comparison to pure PVP electrospun mats which opened a potential route for their use as antibacterial, on-demand, dissolvable coatings for various biomedical applications. Graphical Abstract